MedTrace Logo

Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration

NCT07064759 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 480

Last updated 2026-04-16

No results posted yet for this study

Summary

A Phase 3, Randomized, Double-Masked, Active-Controlled Trial in Adults with Macular Neovascularization Secondary to Age-Related Macular Degeneration

Conditions

  • Neovascular Age-Related Macular Degeneration (nAMD)

Interventions

BIOLOGICAL

4D-150 IVT (3E10 vg/eye)

If randomized to the 4D-150 treatment arm, 4D-150 will be administered at the assigned dose level as a single dose IVT injection on Day 1

BIOLOGICAL

EYLEA® (aflibercept) Injection 2 mg (0.05mL)

Eylea (aflibercept) will be administered at applicable visits

Sponsors & Collaborators

  • 4D Molecular Therapeutics

    lead INDUSTRY

Principal Investigators

  • Julie Tsai, MD · 4D Molecular Therapeutics

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-07-22
Primary Completion
2028-11-30
Completion
2029-02-28
FDA Drug
Yes

Countries

  • United States
  • Argentina
  • Australia
  • Bulgaria
  • Germany
  • Hungary
  • Italy
  • Japan
  • Latvia
  • Lithuania
  • Portugal
  • Singapore
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07064759 on ClinicalTrials.gov